- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06516965
En studie for å evaluere effektiviteten og sikkerheten til Povorcitinib hos deltakere med Prurigo Nodularis (STOP-PN2)
En fase 3, randomisert, dobbeltblind, placebokontrollert, effekt- og sikkerhetsstudie av Povorcitinib hos deltakere med Prurigo Nodularis
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Fremantle, Australia, 06160
- Fremantle Dermatology
-
-
New South Wales
-
Charlestown, New South Wales, Australia, 02290
- Novatrials
-
Kogarah, New South Wales, Australia, 02217
- Premier Specialists Pty Ltd
-
Sydney, New South Wales, Australia, 02010
- Skin & Cancer Foundation Australia
-
Westmead, New South Wales, Australia, 02145
- Westmead Hospital
-
-
Queensland
-
Woolloongabba, Queensland, Australia, 04102
- Veracity Clinical Research Pty Ltd
-
-
Victoria
-
Melbourne, Victoria, Australia, 03004
- The Alfred Hospital
-
-
-
-
-
Bruges, Belgia, 08000
- Az Sint-Jan Brugge Av
-
Ghent, Belgia, 09000
- Universitair Ziekenhuis Gent (Uz Gent)
-
Gilly, Belgia, 06060
- Grand Hopital de Charleroi - Site Imtr
-
Liège, Belgia, 04000
- Centre Hospitalier Universitaire (Chu) de Liege - Domaine Universitaire Du Sart Tilman
-
Woluwe-Saint-Lambert, Belgia, 01200
- Universite Catholique de Louvain (Ucl) - Cliniques Universitaires Saint-Luc
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6W 4V4
- Skin Physicians
-
Edmonton, Alberta, Canada, T6X 0N9
- Alpha Research-Lucere Dermatology and Laser Clinic
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 7G1
- Simcoderm Medical and Surgical Dermatology Centre
-
London, Ontario, Canada, N6H 5L5
- Dermeffects
-
Toronto, Ontario, Canada, M2N 3A6
- North York Research Inc.
-
Toronto, Ontario, Canada, M3H 5Y8
- Toronto Research Centre
-
-
Quebec
-
Québec, Quebec, Canada, G1W 4R4
- Centre de Recherche Saint-Louis
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7K 2C1
- Skinsense Medical Research
-
-
-
-
-
Santiago, Chile, 7580206
- Centro Medico Skinmed Limitada
-
Santiago, Chile, 8420383
- Centro Internacional de Estudios Clinicos
-
Valdivia, Chile, 5090000
- Clinical Research Chile Spa.
-
-
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85006
- Medical Dermatology Specialists Phoenix
-
Scottsdale, Arizona, Forente stater, 85255
- Investigate Md
-
-
California
-
Fountain Valley, California, Forente stater, 92708-3701
- First Oc Dermatology Research Inc
-
Santa Monica, California, Forente stater, 90404
- Clinical Science Institute Clinical Research Specialists Inc
-
-
Florida
-
Aventura, Florida, Forente stater, 33180
- Center For Clinical and Cosmetic Research
-
Boca Raton, Florida, Forente stater, 33428
- Schweiger Dermatology
-
Hialeah, Florida, Forente stater, 33012
- Direct Helpers Research Center
-
Hollywood, Florida, Forente stater, 33201
- Skin Care Research, Llc
-
Miami, Florida, Forente stater, 33162
- Ziaderm Research, Llc
-
Tampa, Florida, Forente stater, 33609
- Trueblue Clinical Research Moore Clinical Research, Inc McR Tampa Clinic Location
-
Tampa, Florida, Forente stater, 33607
- Nodal Medical Center, Llc
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40241
- Dermatology Specialists Research
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21201
- University of Maryland School of Medicine
-
Rockville, Maryland, Forente stater, 20850
- Dermatology Associates Pc
-
-
Massachusetts
-
Brighton, Massachusetts, Forente stater, 02135-3511
- Metro Boston Clinical Partners
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48103
- Fivenson Dermatology
-
Detroit, Michigan, Forente stater, 48202
- Henry Ford Health System
-
Waterford, Michigan, Forente stater, 48328
- Michigan Dermatology Institute
-
-
New Hampshire
-
Portsmouth, New Hampshire, Forente stater, 03801
- Allcutis Research, Llc
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Schweiger Dermatology
-
-
New York
-
New York, New York, Forente stater, 10128
- OPTISKIN
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45267
- University of Cincinnati Cancer Institute
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73118
- Central Sooner Research
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19103
- Paddington Testing Co Inc
-
Yardley, Pennsylvania, Forente stater, 19067
- Yardley Dermatology Associates
-
-
Texas
-
Dallas, Texas, Forente stater, 75231
- Modern Research Associates Pllc
-
-
Utah
-
Murray, Utah, Forente stater, 84107
- University of Utah Midvalley Dermatology
-
-
Washington
-
Burien, Washington, Forente stater, 98168
- Aesthetic General Dermatology of Seattle
-
-
-
-
-
Bunkyō City, Japan, 113-8519
- Tokyo Medical and Dental University Hospital, Faculty of Medicine
-
Inashiki-gun, Japan
- Tokyo Medical University Ibaraki Medical Center - Kasumigaura Campus (Tokyo Medical University Kasum
-
Kamimashiki-gun, Japan, 861-3101
- Noguchi Dermatology Clinic
-
Kawasaki-shi, Japan, 211-8533
- Nippon Medical School Musashikosugi Hospital
-
Kitakyushu, Japan, 807-8555
- University of Occupational and Environmental Health, Japan
-
Kobe, Japan, 657-0846
- Shimizu Dermatology Clinic
-
Kumamoto, Japan, 861-2236
- Aoi Dermatology Clinic
-
Minamikoshigaya, Japan, 343-8555
- Dokkyo Medical University Saitama Medical Center
-
Minokamo, Japan, 505-8510
- Central Japan International Medical Center
-
Niigata, Japan, 951-8520
- Niigata University Medical & Dental Hospital
-
Osaka, Japan, 558-0003
- Medical Corporation Jun Dermatology Clinic
-
Sakai, Japan, 593-8324
- Kume Derma Clinic
-
Sapporo, Japan, 600063
- Sapporo Skin Clinic
-
Sendai, Japan, 980-8574
- Tohoku University Hospital
-
Shinjuku-ku, Japan, 160-0023
- Tokyo Medical University Hospital
-
Tokorozawa, Japan, 359-0042
- National Defense Medical College Hospital
-
Yokohama, Japan, 221-0825
- Nomura Dermatology Clinic
-
Yokohama, Japan, 220-6208
- Queen'S Square Medical Facilities
-
Ōta-ku, Japan, 143-0023
- Tanpopo Dermatology Clinic
-
-
-
-
-
Gdansk, Polen, 80-280
- Akk Medical Sp. Z O.O. - Centrum Medyczne Tu Sie Leczy
-
Katowice, Polen, 40-568
- Care Clinic Sp. Z O.O.
-
Lodz, Polen, 90-436
- Dermoklinika Centrum Medyczne S.C., M. Kierstan, J. Narbutt, A. Lesiak
-
Lodz, Polen, 90-302
- Santa Familia Ptg Lodz
-
Lublin, Polen, 20-573
- Luxderm Specjalistyczny Gabinet Dermatologiczny Prof. Dr. Hab. N. Med. Dorota Krasowska
-
Poznan, Polen, 61-731
- Clinical Research Center Spolka Z Ograniczona Odpowiedzialnoscia Medic-R Spolka Komandytowa
-
Rzeszów, Polen, 35-055
- Uniwersytecki Szpital Kliniczny Im. Fryderyka Chopina W Rzeszowie
-
Torun, Polen, 87-100
- Mics Centrum Medyczne Torun
-
Warsaw, Polen, 02-692
- Royalderm Agnieszka Nawrocka
-
Warsaw, Polen, 01-817
- High-Med. Przychodnia Specjalistyczna
-
Warsaw, Polen, 02-507
- Panstwowy Instytut Medyczny Mswia
-
Wroclaw, Polen, 50566
- Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spolka Partnerska
-
-
-
-
-
Alicante, Spania, 03010
- Hospital General Universitario Dr Balmis
-
Badalona, Spania, 08916
- Hospital Universitari Germans Trias I Pujol (Hugtp)
-
Barcelona, Spania, 08041
- Hospital de La Santa Creu I Sant Pau
-
Córdoba, Spania, 14004
- Hospital Universitario Reina Sofia
-
Granada, Spania, 18016
- Hospital Clinico Universitario San Cecilio
-
Madrid, Spania, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spania, 28046
- Hospital Universitario La Paz
-
Madrid, Spania, 28034
- Hospital Universitario Ramon Y Cajal
-
Majadahonda, Spania, 28222
- Hospital Universitario Puerta de Hierro de Majadahonda
-
Manises, Spania, 46940
- Hospital de Manises
-
Santiago de Compostela, Spania, 15706
- Area Sanitaria de Santiago de Compostela Y Barbanza - Complejo Hospitalario Universitario de Santiag
-
Seville, Spania, 41013
- Hospital Universitario Virgen Del Rocio
-
Valencia, Spania, 46026
- Universitat de Valencia - Hospital Universitari I Politecnic La Fe de Valencia (Hospital La Fe Bulev
-
-
-
-
-
Dudley, Storbritannia, DY1 2HQ
- The Dudley Group Nhs Foundation Trust
-
Ipswich, Storbritannia, IP4 5PD
- Ipswich Hospital, East Suffolk and North Essex Nhs Foundation Trust
-
Liverpool, Storbritannia, L14 3LB
- Broadgreen Hospital - Liverpool University Hospitals Nhs Foundation Trust
-
London, Storbritannia, SE1 9RT
- Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust
-
London, Storbritannia, E1 1FR
- The Royal London Hospital - Barts Health Nhs Trust
-
Poole, Storbritannia, BH15 2JB
- Poole Hospital - University Hospitals Dorset Nhs Foundation Trust
-
Redhill, Storbritannia
- Surrey and Sussex Healthcare Nhs Trust - East Surrey Hospital
-
-
-
-
-
Prague, Tsjekkia, 158 00
- Sanixtra Prague
-
Prague, Tsjekkia, 100 00
- Clintrial S.R.O.
-
Prague, Tsjekkia, 110 00
- Sanatorium Profesora Arenbergera
-
-
-
-
-
Aachen, Tyskland, 52074
- University Hospital Rwth Aachen
-
Buxtehude, Tyskland, 21614
- Elbe Kliniken Buxtehude
-
Chemnitz, Tyskland, 09117
- Drk Krankenhaus Chemnitz-Rabenstein
-
Darmstadt, Tyskland, 64283
- Klinikum Darmstadt
-
Darmstadt, Tyskland, 64283
- Rosenpark Research Gmbh
-
Dresden, Tyskland, 01307
- University Hospital Carl Gustav Carus
-
Frankfurt am Main, Tyskland, 60590
- Klinikum Der Johann Wolfgang Goethe-Universitaet
-
Göttingen, Tyskland, 37075
- Universitaetsmedizin Goettingen
-
Magdeburg, Tyskland, 39104
- Magdeburger Company For Medical Studies and Services Gmbh
-
Mainz, Tyskland, 55128
- Dermatologische Gemeinschaftspraxis Dres. Quist
-
München, Tyskland, 80802
- Technischen Universitaet Muenchen
-
Münster, Tyskland, 48149
- University Hospital Muenster
-
Oldenburg, Tyskland, 26133
- Klinikum Oldenburg Aor
-
Witten, Tyskland, 58453
- Hautarztpraxis Dr. Hoffmann
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male and female participants 18 to 75 years of age.
- Clinical diagnosis of PN for at least 3 months prior to Screening visit.
- Pruritus, defined as an average Itch NRS score ≥ 7 during the 7 days prior to Day 1/Baseline.
- Total of ≥ 20 pruriginous lesions on ≥ 2 different body regions (both legs, and/or both arms, and/or trunk) at Screening and Day 1/Baseline.
- Documented history of treatment failure, demonstrated intolerance, or contraindication to a previous PN treatment.
- Willingness to avoid pregnancy or fathering children.
Exclusion Criteria:
- Chronic pruritus due to a condition other than PN or neuropathic and psychogenic pruritus.
- Diagnosis of PN secondary to medications.
- Active AD lesions (signs and symptoms other than dry skin) within 3 months prior to Screening visit.
- Women who are pregnant (or are considering pregnancy) or breastfeeding.
- Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.
- Evidence of infection with TB, HBV, HCV or HIV.
- History of failure to any topical or systemic JAK or TYK2 inhibitor as treatment of PN or any inflammatory disease.
- Laboratory values outside of the protocol-defined ranges.
Other protocol-defined Inclusion/Exclusion Criteria apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Povorcitinib Dose 1
Povorcitinib at the protocol-defined dose. |
Oral Tablet
Andre navn:
|
|
Eksperimentell: Povorcitinib Dose 2
Povorcitinib at the protocol-defined dose. |
Oral Tablet
Andre navn:
|
|
Placebo komparator: Placebo
Placebo at the protocol-defined dose. |
Oral Tablet |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24
Tidsramme: Week 24
|
Defined as proportion of participants achieving a ≥ 4-point improvement [reduction] in Itch NRS score from baseline (Itch NRS4) and an IGA CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline (IGA-CPG-S-TS). |
Week 24
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of participants achieving Itch NRS4 at Week 24
Tidsramme: Week 24
|
Defined as percentage of participants that achieve a ≥ 4-point improvement (reduction) in Itch NRS score from baseline. |
Week 24
|
|
Proportion of participants achieving IGA-CPG-S-TS at Week 24
Tidsramme: Week 24
|
Defined as percentage of participants that achieve IGA-CPG-S score of 0 or 1 with a ≥ 2 grade improvement from baseline. |
Week 24
|
|
Proportion of participants achieving Itch NRS4 at Week 4
Tidsramme: Week 4
|
Defined as percentage of participants that achieve a ≥ 4-point improvement (reduction) in Itch NRS score from baseline. |
Week 4
|
|
Time to Itch NRS4
Tidsramme: Up to 52 Weeks
|
Defined as time taken for the participant to achieve a ≥4 improvement in Itch NRS score from baseline. |
Up to 52 Weeks
|
|
Change from baseline in Itch NRS score at each postbaseline visit
Tidsramme: Up to 52 weeks
|
Itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". |
Up to 52 weeks
|
|
Percent change from baseline in NRS score at each postbaseline visit
Tidsramme: Up to 52 weeks
|
Itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". |
Up to 52 weeks
|
|
Proportion of participants achieving Itch NRS4 at each postbaseline visit
Tidsramme: Up to 52 weeks
|
Defined as percentage of participants that achieve a ≥ 4-point improvement in Itch NRS score from baseline. |
Up to 52 weeks
|
|
Proportion of participants achieving IGA-CPG-S-TS at each postbaseline visit
Tidsramme: Up to 52 weeks
|
Defined as percentage of participants that achieve an IGA-CPG-S score of 0 or 1 with a ≥ 2 grade improvement from baseline. |
Up to 52 weeks
|
|
Proportion of participants achieving Investigator's Global Assessment - Chronic Prurigo Activity (IGA-CPG-A) at each postbaseline visit
Tidsramme: Up to 52 weeks
|
Defined as percentage of participants that achieve an IGA-CPG-A score of 0 or 1 with a ≥ 2 grade improvement (reduction) from baseline. |
Up to 52 weeks
|
|
Proportion of participants achieving ≥ 75% healed lesions in Prurigo Activity Score (PAS) at each postbaseline visit
Tidsramme: Up to 52 weeks
|
The modified PAS will be used in this study as defined by the protocol. |
Up to 52 weeks
|
|
Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at each postbaseline visit
Tidsramme: Up to 52 weeks
|
Defined as percentage of participants that achieve a ≥ 4-point improvement (reduction) in Itch NRS score and IGA-CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline. |
Up to 52 weeks
|
|
Change from baseline in Dermatology Life Quality Index (DLQI) score at each postbaseline visit.
Tidsramme: Up to 52 weeks
|
The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. |
Up to 52 weeks
|
|
Percent change from baseline in Dermatology Life Quality Index (DLQI) score at each postbaseline visit.
Tidsramme: Up to 52 weeks
|
The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. |
Up to 52 weeks
|
|
Proportion of participants with at least a 4-point decrease in DLQI score from baseline at each postbaseline visit for participants with DLQI score ≥ 4 at baseline
Tidsramme: Up to 52 weeks
|
Defined as percentage of participants with at least a 4-point decrease in DLQI score from baseline at each postbaseline visit for participants with DLQI score ≥ 4 at baseline. |
Up to 52 weeks
|
|
Change from baseline in Skin Pain NRS score at each postbaseline visit
Tidsramme: Up to 52 weeks
|
Skin Pain NRS is an 11-point scale (0 to10) where 0 is "no pain" and 10 is the "worst pain imaginable". |
Up to 52 weeks
|
|
Percent change from baseline in Skin Pain NRS score at each postbaseline visit
Tidsramme: Up to 52 weeks
|
Skin Pain NRS is an 11-point scale (0 to10) where 0 is "no pain" and 10 is the "worst pain imaginable". |
Up to 52 weeks
|
|
Change from baseline in the Hospital Anxiety and Depression Scale (HADS) score at each postbasline visit
Tidsramme: Up to 52 weeks
|
HADS is a 14-item questionnaire that assesses the levels of anxiety and depression that a participant is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question (responses are scored as 0, 1, 2, or 3). |
Up to 52 weeks
|
|
Percent change from baseline in the HADS score at each postbaseline visit
Tidsramme: Up to 52 weeks
|
HADS is a 14-item questionnaire that assesses the levels of anxiety and depression that a participant is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question (responses are scored as 0, 1, 2, or 3). |
Up to 52 weeks
|
|
Change from baseline in EQ-5D-5L score at each postbaseline visit
Tidsramme: Up to 52 weeks
|
The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome. |
Up to 52 weeks
|
|
Percent change from baseline in EQ-5D-5L score at each postbaseline visit
Tidsramme: Up to 52 weeks
|
The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome. |
Up to 52 weeks
|
|
Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) score at each postbaseline visit
Tidsramme: Up to 52 weeks
|
The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days. |
Up to 52 weeks
|
|
Percent change in FACIT-F score at each postbaseline visit
Tidsramme: Up to 52 weeks
|
The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days. |
Up to 52 weeks
|
|
Proportion of participants with at least a ≥ 4-point increase in FACIT-F score at each postbaseline visit for participants with FACIT-F score ≤ 48 at baseline
Tidsramme: Up to 52 weeks
|
The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days. |
Up to 52 weeks
|
|
Number of Participants with Treatment Emergent Adverse Events (TEAE)
Tidsramme: Up to 52 weeks
|
Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug. |
Up to 52 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Incyte Medical Monitor, Incyte Corporation
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- INCB54707-306
- 2024-511881-35-00 (Registeridentifikator: EU CT Number)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD-delingstidsramme
Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Tilgangskriterier for IPD-deling
Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .